- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01573546
ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement (ENLIGHTEN)
April 17, 2018 updated by: Duke University
Lifestyle, CVD Risk, and Cognitive Impairment
ENLIGHTEN will examine the effects of exercise, the dietary approaches to stop hypertension diet (DASH), and a combined exercise and DASH intervention on cognitive function among adults with cardiovascular disease (CVD) risk and cognitive deficits.
Participants will be randomized to one of the three treatments, or a health education control condition, for 6 months, and will complete assessments of CVD health and cognitive function before and after treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death and disability in the United States, affecting more than 81 million American adults.
It is well established that risk factors such as hypertension, diabetes, and hyperlipidemia not only place individuals at risk for CVD, but also place them at risk for neurocognitive impairment and dementia.
CVD risk factors have been shown to be associated with a cascade of neurophysiologic and neuroanatomic changes, resulting in cognitive impairment and dementia.
Exercise and diet have been shown to improve CVD risk factors and also appear particularly promising lifestyle approaches for preventing dementia among individuals at risk, such as those with cognitive impairment, no dementia (CIND).
ENLIGHTEN is a randomized clinical trial of diet and exercise among patients with CIND.
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 55 years or older
- Sedentary
- Score of 19-25 on the Montreal Cognitive Assessment Battery or verbal fluency score of =< 12 or animal fluency score of =<15
- At least one cardiovascular risk factor (hypertension, diabetes, cholesterol, obesity, current smoking, or family history) or a documented history of cardiac disease (myocardial infarction, coronary artery bypass grafting, peripheral vascular disease, >70% stenosis, or mild stroke without residual deficit)
Exclusion Criteria:
- Any significant neurological disease other than CIND, such as Parkinson's disease, multi-infarct dementia, Huntington' s disease, progressive supranuclear palsy, brain tumor, normal pressure hydrocephalus, subdural hematoma, seizure disorder, multiple sclerosis, or history of head trauma with persistent neurological deficits
- Psychotic disorder within the past two years (DSM IV criteria) or acutely suicidal
- History of alcohol or substance abuse or dependence within the past two years (DSM IV criteria)
- History of schizophrenia
- Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol including a history of systemic cancer within the past 5 years (nonmetastatic skin cancers are acceptable)
- Myocardial infarction (within the past 3 months) or unstable or severe congestive heart failure (e.g. class III-IV heart failure)
- End-stage pulmonary disease; uncontrolled diabetes mellitus or uncontrolled hypertension(systolic BP>170 or diastolic BP >100 mm Hg on medication)
- Musculoskeletal disorders precluding the ability to exercise (e.g. severe arthritis)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerobic Exercise
|
Participants will exercise for 6 months.
In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test.
Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking.
Each exercise session will conclude with a 10 minute period of cool-down exercises.
During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
|
Experimental: DASH diet
|
Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines.
Participants will be explicitly asked not to exercise and to focus their attention on what they eat.
Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health.
Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period.
Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
|
Experimental: Combined aerobic exercise and DASH diet
|
Participants will exercise for 6 months.
In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test.
Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking.
Each exercise session will conclude with a 10 minute period of cool-down exercises.
During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines.
Participants will be explicitly asked not to exercise and to focus their attention on what they eat.
Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health.
Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period.
Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
|
Active Comparator: Health education control
|
The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted.
These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated.
These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Executive Function
Time Frame: Baseline to post-treatment assessment at 6 months
|
Composite executive function measure includes Trail Making Test, Stroop Test, Digit Span, Digit Symbol Substitution Test, Ruff 2 & 7 Test, and Animal Naming Test
|
Baseline to post-treatment assessment at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Memory
Time Frame: 6 months
|
Secondary outcomes will include composite measures of memory (Hopkins Verbal Learning Test-Revised and Medical College of Georgia Complex Figure Test)
|
6 months
|
Change in Language
Time Frame: 6 months
|
Secondary outcomes will include composite measures of language (Controlled Oral Word Association Test and Animal Naming Test)
|
6 months
|
Inflammation
Time Frame: 6 months
|
We will also assess treatment effects on measures of inflammation, including C-reactive protein and interleukin-6.
|
6 months
|
Functional Capacity
Time Frame: 6 months
|
Functional capacity (6MWT and peak VO2).
Six-minute walk distance (6MWT) and peak VO2 from a treadmill test will be assessed by an exercise physiologist.
|
6 months
|
Blood Pressure
Time Frame: 6 months
|
We also will examine treatment effects on the vascular function measures, including blood pressure.
|
6 months
|
Flow-mediated dilation of the brachial artery
Time Frame: 6 months
|
We also will examine treatment effects on the vascular function measures, including flow-mediated dilation of the brachial artery.
|
6 months
|
Arterial Stiffness
Time Frame: 6 months
|
We also will examine treatment effects on the vascular function measures, including pulse-wave velocity of the femoral artery.
|
6 months
|
Intima-medial thickness
Time Frame: 6 months
|
We also will examine treatment effects on the vascular function measures, including intima-medial thickness of the carotid artery.
|
6 months
|
Fasting glucose
Time Frame: 6 months
|
We will also assess treatment effects on measures fasting glucose
|
6 months
|
Cholesterol
Time Frame: 6 months
|
We will also examine treatment effects on cholesterol, including LDL, HDL, and total cholesterol
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: James A Blumenthal, PhD, Duke University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Blumenthal JA, Smith PJ, Welsh-Bohmer K, Babyak MA, Browndyke J, Lin PH, Doraiswamy PM, Burke J, Kraus W, Hinderliter A, Sherwood A. Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. Contemp Clin Trials. 2013 Jan;34(1):60-9. doi: 10.1016/j.cct.2012.09.004. Epub 2012 Sep 19.
- Blumenthal JA, Smith PJ, Mabe S, Hinderliter A, Welsh-Bohmer K, Browndyke JN, Doraiswamy PM, Lin PH, Kraus WE, Burke JR, Sherwood A. Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial. J Am Geriatr Soc. 2020 Mar;68(3):559-568. doi: 10.1111/jgs.16252. Epub 2019 Nov 22.
- Blumenthal JA, Smith PJ, Mabe S, Hinderliter A, Lin PH, Liao L, Welsh-Bohmer KA, Browndyke JN, Kraus WE, Doraiswamy PM, Burke JR, Sherwood A. Lifestyle and neurocognition in older adults with cognitive impairments: A randomized trial. Neurology. 2019 Jan 15;92(3):e212-e223. doi: 10.1212/WNL.0000000000006784. Epub 2018 Dec 19.
- Blumenthal JA, Smith PJ, Mabe S, Hinderliter A, Welsh-Bohmer K, Browndyke JN, Lin PH, Kraus W, Doraiswamy PM, Burke J, Sherwood A. Lifestyle and Neurocognition in Older Adults With Cardiovascular Risk Factors and Cognitive Impairment. Psychosom Med. 2017 Jul/Aug;79(6):719-727. doi: 10.1097/PSY.0000000000000474.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
March 1, 2018
Study Registration Dates
First Submitted
December 22, 2011
First Submitted That Met QC Criteria
April 5, 2012
First Posted (Estimate)
April 9, 2012
Study Record Updates
Last Update Posted (Actual)
April 18, 2018
Last Update Submitted That Met QC Criteria
April 17, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00031464
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Impairment, no Dementia (CIND)
-
Sunnybrook Health Sciences CentreCompletedVascular Cognitive Impairment no DementiaCanada
-
Beijing Friendship HospitalXuanwu Hospital, Beijing; Fu Xing Hospital, Capital Medical UniversityCompletedVascular Cognitive Impairment no DementiaChina
-
The Second Hospital of Hebei Medical UniversityUnknownVascular Cognitive Impairment no DementiaChina
-
BaycrestActive, not recruitingCognitive Change | Mild Cognitive Impairment | Dementia Prevention | Subjective Cognitive ImpairmentCanada
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecruitingDementia | Mild Cognitive Impairment | Dementia, Mixed | Dementia of Alzheimer Type | Subjective Cognitive Impairment | Dementia SenileSweden
-
BaycrestCompletedDementia | Mild Cognitive Impairment | Dementia Prevention | Subjective Cognitive Impairment | Pre-dementiaCanada
-
Conor MartinBetsi Cadwaladr University Health BoardUnknownCognitive Impairment - e.g. DementiaUnited Kingdom
-
University Hospital, RouenCentre Hospitalier Intercommunal Elbeuf-Louviers / Val de ReuilUnknown
-
National Taiwan University HospitalUnknownMild Cognitive Impairment, DementiaTaiwan
Clinical Trials on Aerobic Exercise
-
Riphah International UniversityCompleted
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPhysical InactivityTurkey
-
University of FloridaAmerican Psychological Foundation; Clinical & Translational Science Institute; American Psychological Association (APA)CompletedBrain ConcussionUnited States
-
Radboud University Medical CenterUniversity Hospital, Bonn; University of Dublin, Trinity College; German Sport... and other collaboratorsCompletedMild Cognitive ImpairmentNetherlands, Ireland, Germany
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
National Yang Ming UniversityUnknownKnee OsteoarthritisTaiwan
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanRecruitingCardiology | PsychiatryTaiwan
-
Federal University of PelotasMinistry of Health, BrazilUnknownHypertension | Cardiovascular Disease | Chronic Kidney Disease | Chronic Renal DiseaseBrazil
-
University of Kansas Medical CenterRecruiting
-
Lithuanian University of Health SciencesCompletedMigraine | Temporomandibular Joint Disorders | Myofascial Trigger Point PainLithuania